Dermapharm Holding SE Capital Reinvestment Ratio
Dermapharm Holding SE capital reinvestment ratio. Dermapharm Holding SE (DMP) has a Capital Reinvestment Ratio of 0.30x as of March 2026, meaning it reinvests 0% of its operating cash flow (€39.49 Million) in capital expenditures (€11.85 Million). See Dermapharm Holding SE free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Dermapharm Holding SE (2014–2025)
Capital reinvestment ratio of Dermapharm Holding SE from 2014 to 2025. This chart tracks Dermapharm Holding SE's Capital Reinvestment Ratio across 12 annual periods. See how financially flexible is Dermapharm Holding SE to measure the company's free cash flow as a share of total liabilities.
Dermapharm Holding SE Capital Reinvestment Ratio by Year (2014–2025)
Dermapharm Holding SE capital reinvestment ratio by year from 2014 to 2025. For the full cash flow conversion analysis, see DMP cash generation efficiency.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.23x | €181.51 Million | €42.12 Million | ▲ +22.2% |
| 2024 | 0.19x | €201.38 Million | €38.24 Million | ▲ +0.3% |
| 2023 | 0.19x | €219.42 Million | €41.54 Million | ▲ +40.0% |
| 2022 | 0.14x | €288.53 Million | €39.01 Million | ▼ -44.7% |
| 2021 | 0.24x | €250.37 Million | €61.20 Million | ▼ -21.4% |
| 2020 | 0.31x | €131.10 Million | €40.80 Million | ▼ -32.6% |
| 2019 | 0.46x | €100.61 Million | €46.44 Million | ▲ +182.8% |
| 2018 | 0.16x | €159.13 Million | €25.97 Million | ▼ -81.1% |
| 2017 | 0.86x | €86.74 Million | €74.72 Million | ▲ +272.4% |
| 2016 | 0.23x | €76.78 Million | €17.76 Million | ▼ -37.5% |
| 2015 | 0.37x | €40.38 Million | €14.93 Million | ▼ -29.4% |
| 2014 | 0.52x | €54.26 Million | €28.42 Million | — |